About Sai Parenterals

IPO date

24th – 27th Mar 2026

Listing date

02 Apr 2026

Price range

₹370 – ₹392 Lot size 38 — ₹14896

Issue size

409cr

Sai Parenteral’s Limited is a diversified pharmaceutical formulations company incorporated in January 2001. It was originally established as a private limited company and was converted into a public limited company in January 2022. Anil Kumar Karusala, Vijitha Gorrepati and Karusala Aruna promote the Company. The Company operates across branded generic formulations and contract development and manufacturing (CDMO) services. Its product portfolio spans multiple therapeutic areas, including cardiovascular, neuropsychiatry, anti-diabetic, antibiotics, gastroenterology, respiratory care, dermatology, and vitamins and supplements. Offerings cover a wide range of dosage forms such as injectables, tablets, capsules, liquid orals and ointments. Sai Parenteral has strong capabilities in sterile injectable manufacturing, including dry powder injections, vials, ampoules and pre-filled syringes. Its operations are supported by multiple manufacturing facilities in Telangana and Andhra Pradesh, along with in-house research and development capabilities. The Company follows an integrated business model, combining product development, manufacturing and customer-centric execution. Its key strengths include diversified product offerings, established manufacturing infrastructure, regulatory-focused processes and long-standing promoter-led management experience.